Aadi Bioscience, Inc. AADI
Institutional shares held
12.6 Million
23.8K
calls
0
puts
Total value of holdings
$29.2M
$55K
calls
$0
puts
Market Cap
$71.2M
21,016,800
Shares Out.
Institutional ownership
59.84%
# of Institutions
55
We take great care to ensure that the data presented and summarized in this overview for Aadi Bioscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AADI
View all-
Avoro Capital Advisors LLC New York, NY2.85MShares$9.66 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$6.78 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$6.27 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$6.26 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$2.6 Million0.0% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC526KShares$1.78 Million1.41% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny462KShares$1.57 Million0.0% of portfolio
-
Acuitas Investments, LLC439KShares$1.49 Million0.43% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT333KShares$1.13 Million0.06% of portfolio
-
Black Rock Inc. New York, NY320KShares$1.09 Million0.0% of portfolio
Latest Institutional Activity in AADI
Top Purchases
Top Sells
About AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Insider Transactions at AADI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2024
|
David James Lennon CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,689
-29.76%
|
$9,689
$1.94 P/Share
|
|
Oct 02
2024
|
David James Lennon CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
32,558
+50.0%
|
-
|
|
Sep 03
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
40,000
-3.3%
|
$40,000
$1.71 P/Share
|
|
Aug 05
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,652
-0.46%
|
$5,652
$1.34 P/Share
|
|
Aug 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
18,933
-1.53%
|
$18,933
$1.41 P/Share
|
|
Aug 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
15,415
-1.23%
|
$15,415
$1.5 P/Share
|
|
Jul 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
8,652
-0.69%
|
$8,652
$1.34 P/Share
|
|
Jul 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
31,348
-2.43%
|
$31,348
$1.45 P/Share
|
|
Jun 04
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
20,225
-1.54%
|
$20,225
$1.77 P/Share
|
|
Jun 03
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
19,775
-1.49%
|
$19,775
$1.81 P/Share
|
|
May 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
40,000
-2.92%
|
$40,000
$1.93 P/Share
|
|
Apr 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
22,228
-1.59%
|
$44,456
$2.23 P/Share
|
|
Apr 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
17,772
-1.26%
|
$35,544
$2.31 P/Share
|
|
Mar 04
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
14,964
-1.05%
|
$29,928
$2.1 P/Share
|
|
Mar 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
27,036
-1.86%
|
$27,036
$1.97 P/Share
|
|
Feb 01
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
42,000
-2.81%
|
$42,000
$1.74 P/Share
|
|
Jan 02
2024
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
42,000
-2.73%
|
$84,000
$2.06 P/Share
|
|
Dec 06
2023
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
7,037
-0.46%
|
$28,148
$4.82 P/Share
|
|
Dec 05
2023
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
15,740
-1.01%
|
$78,700
$5.02 P/Share
|
|
Dec 04
2023
|
Neil Desai EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
10,876
-0.69%
|
$54,380
$5.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
32.6K
Shares
From
1
Insiders
| Exercise of conversion of derivative security | 32.6K shares |
|---|
Sell / Disposition
376K
Shares
From
2
Insiders
| Open market or private sale | 376K shares |
|---|